



**A NEET SS (SURGERY) PREPARATION COURSE
BY MARROW, WITH A TEAM OF SELECTED
SUPER-SPECIALITY FACULTY**

SURGERY NEET SS

oncology

**PREPARATION COURSE
BY MARROW, WITH A TEAM OF
SELECTED
SUPER-SPECIALITY FACULTY**

CONTENT

1)	PRINCIPLES OF CANCER STAGING	1
2)	ETIOLOGY OF CANCER 1	6
3)	ETIOLOGY OF CANCER 2	14
4)	ONCOGENIC VIRUSES 1	18
5)	ONCOGENIC VIRUSES 2	21
6)	CANCER SCREENING	24
7)	RADIOTHERAPY IN ONCOLOGY 1	31
8)	RADIOTHERAPY IN ONCOLOGY 2	41
9)	TOBACCO USE & CANCER PATIENTS	47
10)	ROLE OF SX. IN CANCER PREVENTION	52
11)	RESPONSE EVA. CRITERIA IN SOLID TUM.	61
12)	EMERGENCIES IN ONCOLOGY	65
13)	SALIVARY GLAND TUMOR	73
14)	OVERVIEW OF HEAD & NECK CANCERS	82
15)	PRINCIPLES OF SX. IN MALIG. OF ORAL CA.	99
16)	ORAL CAV. & OROPHARYN. CANCERS	111
17)	HYPOPHAR.,NASAL & SINUS CANCERS	126
18)	NECK DISSECTION	134
19)	GUIDELINES - LARY. CANCER MGT.	151
20)	GUIDELINES - OROPHY. CANCER MGT.	158
21)	GUIDELINES - NASO. CANCER MGT.	165
22)	NON SMALL CELL LUNG CANCER 1	170
23)	NON SMALL CELL LUNG CANCER 2	187
24)	NON SMALL CELL LUNG CANCER 3	201
25)	SMALL CELL LUNG CANCER	211
26)	NET OF LUNG	217
27)	MEDIASTINAL NEOPLASMA	223
28)	MESOTHELIOMA	236
29)	ESOPH. CANCER : INTRO. & EVALU.	251
30)	ESOPHAGEAL CANCER : MANAGEMENT	258
31)	GASTROESOPHAGEAL JUNCTION TUMORS	264
32)	GASTRIC CANCER 1	271
33)	GASTRIC CANCER 2	277

34)	SMALL BOWEL TUMORS	284
35)	COLON CANCER	291
36)	COLON CANCER MGT.	295
37)	MGT. OF POLYPS	304
38)	RECTAL CANCER	310
39)	CARCINOMA APPENDIX	316
40)	HCC:CLINICAL FEAT. & EVALUATION	321
41)	HCC:STAGING & MGT.	329
42)	GALLBLADDER CANCER	342
43)	BILE DUCT CANCER	354
44)	PANCREATIC CANCER	367
45)	GIST	382
46)	GIST UPDATES	394
47)	KIDNEY CANCER	397
48)	BLADDER CANCER 1	403
49)	BLADDER CANCER 2	410
50)	PENILE CANCER	415
51)	TESTICULAR CANCER 1	423
52)	TESTICULAR CANCER 2	428
53)	CERVICAL CANCER	437
54)	CERVICAL INTRAPITHELIAL NEO.	440
55)	CACINOMA ENDOMETRIUM	452
56)	OVARIAN CANCER 1	461
57)	OVARIAN CANCER 2	468
58)	OVARIAN CANCER 3	479
59)	VAGINAL CARCINOMA VULVAR.	490
60)	CARCINOM A	494
61)	GTN	500
62)	NET 1	506
63)	NET 2	510
64)	DIFFERENTIATED THYROID CANCER 1	519
65)	DIFFERENTIATED THYROID CANCER 2	530
66)	DIFFERENTIATED THYROID CANCER 3	541
67)	DIFFERENTIATED THYROID CANCER 4	556
68)	MEDULLARY THYROID CANCER	564

69)	THYROID CARCINOMA : RT	571
70)	PARATHYROID TUMORS	577
71)	ADRENAL TUMORS	583
72)	PHEOCHROMOCYTOMA	592
73)	MEN SYNDROME 1	597
74)	MEN SYNDROME 2	607
75)	SKIN MALIGNANCY : INTRO.	613
76)	MALIGNANT MELANOMA : MB	619
77)	MALIGNANT MELANOMA : SBT & STAGING	624
78)	MALIGNANT MELANOMA : EV. & MGT.	635
79)	MALIGNANT MELANOMA : ADJ. THERAPY	646
80)	MALIGNANT MELANOMA : UPDATES	653
81)	BASAL CELL CARCINOMA 1	654
82)	BASAL CELL CARCINOMA 2	658
83)	SQUAMOUS CELL CARCINOMA	661
84)	SKIN ADNEXAL TUMOR 1	667
85)	SKIN ADNEXAL TUMOR 2	675
86)	SKIN MALIGNANCY (IMAGE DISCUSSION)	684
87)	BONE TUMORS 1	692
88)	BONE TUMORS 2	700
89)	SOFT TISSUE SARCOMAS 1	710
90)	SOFT TISSUE SARCOMAS 2	722
91)	BREAST 1	732
92)	BREAST 2	741
93)	BREAST 3	747
94)	BREAST 4	760
95)	CARCINOMA OF UNKOWN PRIMARY	768

PRINCIPLES OF CANCER STAGING

Introduction

00:00:10

Purpose : To know the extent of the disease.

TNm Staging :

most widely used staging system.

Anatomical staging system.

3 components :

1. T category : Primary tumor.

- T x
 - T 0.
 - T is.
 - T 1.
 - T 2.
 - T 3.
 - T 4.
- } Invasive

2. N category : Regional lymph nodes (LN).

- N 0 : No nodes.
- N 1.
- N 2.
- N 3.

3. m category : Distant metastasis.

- m 0 : No distant metastasis.
- m 1 : Distant metastasis present.

Has sub-categories like a, b, c, d.

Evidence based system : Upper stage \rightarrow \downarrow Survival.

Eg; Breast cancer :

T 1 : < 2 cm. T 2 : 2-5 cm. T 3 : > 5 cm.

1.8 cm and 1.9 cm tumors : No difference in survival

1.9 cm and 2.1 cm tumors : Sharp difference in survival.

\therefore Cut-off for upper stage is 2 cm.

Staging Groups

00:04:10

Group	Based on
cTNM	Clinical examination Radiological examination Surgical exploration without resection
pTNM	Pathology of resected tumor
yTNM: • ycTNM • ypTNM	Post-Neoadjuvant therapy (NACT)
rTNM: • rcTNM • rpTNM	Recurrence
aTNM	Autopsy (incidental detection)

ycTNM : Clinical/radiological examination post-NACT.

ypTNM : Pathology of resected tumor post-NACT.

rcTNM : Clinical/radiological examination of recurrence.

rpTNM : Pathology of resected tumor of recurrence.

TNM Staging

00:09:40

T (Primary tumour) :

Tx : Cannot be assessed/Information not available.

Eg:

- Primary tumor operated elsewhere with no records.
- Extensive tumor where the primary cannot be identified.

T 0 : No primary tumor.

T is : In situ.

T 1-T 4 : Invasive.

N (Regional nodes) :

N x : Cannot be assessed.

N 0 : No nodes

N 1-N 3 : Nodes present.

m (distant metastasis) :

m 0 : No distant metastasis.

m 1 : Distant metastasis present.

No m x.

multiple tumors : Highest T mentioned.

Eg: Breast cancer :

- 3 tumors are present with largest being 6 cm.
- Staging : pT3 (m)/N 0/m 0 (or) pT 3 (3)/N 0/m 0 where (m) means multiple.
- Actual number of tumors can also be specified like (3).

Synchronous vs. metachronous :

- Cut-off of appearance of multiple tumors is 4 months from the diagnosis of primary.
- <4 months : Synchronous.
- >4 months : metachronous.
- metachronous malignancies are staged separately.
- Synchronous malignancies are staged together.
- Paired organs like lung included in the staging criteria.

Unknown primary :

- Evidence of nodal spread is present.
- Expected primary site does not show up.
- Categorized as T 0.
- Eg:
 - a. Axillary nodes present, no primary seen in breast.
 - b. Clinically → cT 0.
 - c. mastectomy is done and no primary is found → pT0.
 - d. Staging (as per suspected primary site) → Ca. Breast, T 0/N 1/m 0, Stage II.

Regional nodes :

Sentinel node :

- Represented as (sn).
- If only sentinel node biopsy is done then (sn) can be used.
- If complete dissection is done, then (sn) cannot be used.

FNAC proven nodes :

- Represented as (F).
- Eg: FNAC proven NI : pNI (F).


Isolated tumor cells :

- Cluster of < 200 cells.
- Size < 0.2 mm.
- Represented as (i+). Eg: pNI (i+).
- It represents in-transit disease and not something that stations and proliferates.
- It is not considered as node +ve.
- Isolated cells are also considered node positive in aggressive malignancies :
 - a. melanoma
 - b. merkel cell carcinoma.

Stage 0

00:20:13

In situ and non-invasive cancers.



Layers of GIT

Area below the serosa : Subserosa.

If serosa is absent, it is called Adventitia.

- i. In situ : Not crossed a boundary to attain spread (no

spreading potential).

- Boundary can be :
 - a. Basement membrane : Oral cavity.
 - b. Muscularis mucosae : Colon.
- No potential to spread.
- Nodal / distant assessment not needed.

2. Complete Pathological response :

- Seen when tumor disappears after NACT.
- T 0 / N 0 / M 0.
- Not Stage 0 (stage 0 → in-situ).

3. Non-Invasive : Disease has not crossed basement membrane of epithelium.

- Very few cancers.
- Represented as T a.
- Eg : Bladder cancer : pT a / N 0 / M 0.

4. DCIS :

- Can have nodal spread.
- Invasive component maybe missed on pathology.

ETIOLOGY OF CANCER I

Etiology & factors responsible for carcinogenesis

00:00:10

Rudolf Virchow proposed that lymphoreticular infiltrate in a tumor originates from chronic inflammation.

Types of inflammation :

Tumor intrinsic	Tumor extrinsic
Cancer initiates and amplifies the inflammatory pathway → Promote survival, growth & invasion.	macroscopic environment of tumor contributes to carcinogenesis.
<p>E.g.:</p> <ul style="list-style-type: none"> • Aflatoxin & aspergillus (↑ses mutagenesis) causing HCC. • RET mutations → Non invasive follicular thyroid neoplasm → Promotes tumor development (promotion of inflammatory pathway) 	<p>E.g.:</p> <ul style="list-style-type: none"> • Chronic pancreatitis → Pancreatic carcinoma. • H pylori → Stomach cancer. • GERD → Esophageal ca. • Hepatitis → HCC.

Infections causing cancer :

Cancer	Infection
Bladder cancer	Schistosoma haematobium
Burkitt's lymphoma	EBV, HHPV 4
Cervical cancer	HPV
Cholangiocarcinoma	Salmonella typhi, Opisthorchis viverrini, Clonorchis sinensis
Colorectal cancer	JC virus, Streptococcus bovis
Glioma	JC virus

HCC	Hepatitis B, C, D, Schistosoma japonicum, Aflatoxin
Hodgkin's lymphoma	EBV
merkel cell cancer	merkel cell polyoma virus
mesothelioma	SV 40
Adult T cell leukemia/ lymphoma	HTLV I
Prostate cancer	xenotropic murine leukemia virus
Kaposi's sarcoma	HHV 8

Inflammatory mediators

00:08:48

The following have a role in interaction b/w tumor & host immune cells (cytokines):

- Chemokines.
- Interleukins : IL-1, IL-6, IL-8, IL-17.
- Interferons : I (α & β), II (γ), III ($\Delta 1$, $\Delta 2$ & $\Delta 3$).
- Prostaglandins.
- TNF α .

TNF : 1^o mediator of inflammation.

NFKB pathway :

- major role in cancer.
- Activator of TNF.
- Initiation & transformation.

mechanism :

Inflammation \rightarrow Cytokines \rightarrow Promote release of inflammatory cells \rightarrow Oxidative damage, DNA mutation \rightarrow microenvironment in tissue is more conducive to increased cell growth, survival & transformation.

Survival of cell :

- Pro-inflammatory cytokines : IL-1 β , IL-8, TNF α & CRP
 \uparrow sed levels \rightarrow Reduced survival (poor prognosis).

- STAT 6 & STAT 3 ↑ expression (↑ inflammation) → inverse association of survival in mesothelioma.

Invasion :

- MMP 9 (matrix metalloproteinase 9) :
 - a. Gelatinase which degrades type IV collagen.
 - b. High expression shows poor prognosis (High chance of tumor invasion).
- HIF1α : Increased vascular invasion in HCC → Poor prognosis
- Cathepsin D : Increased association in inflammatory breast cancer.

Angiogenesis :

Pro-angiogenic factors	Factors for angiogenesis
TNFα	MIF : Endothelial cell activation
IL-1β	TGFβ (Head & neck SCC)
IL-8	Angiopoietin-2

Factors for metastasis
VEGF
FGF 2
PDGF
ICAM-1
VCAM-1
E-selectin
P-selectin
mmp-9

Molecular mechanism of carcinogenesis

00:18:00

1. NFκB pathway : Pro-tumorigenic.

Mechanism :

- i. Chronic inflammation → EMT (epithelial mesenchymal transformation) activation → ↑ cell survival by promoting anti-apoptotic proteins → MYC & BCL-XL.

ii. Extracellular matrix remodeling by MMP & VEGF.

2. STAT 1 & 3 : Persistent STAT → Tumor inflammatory signal



Tumor cell survival & angiogenesis

3. Inflammasome :

- Silica & asbestos can trigger inflammasome.
- Activates IL-1β & IL-8 and other mediators (pro-inflammatory).

4. Toll like receptors (TLR) :

- Role in :
 - a. Host defense mechanism
 - b. Tissue injury
- Chronic inflammation → Chronic TLR pathway activation
→ Carcinogenesis.

Chemical factors

00:23:06

Scrotal cancer in chimney sweepers : First environmental cancer discovered by Percival Pott.

Cancer	Chemical carcinogens
Lung	Tobacco, asbestos, nickel.
Pleura	Asbestos.
Oral cavity	Tobacco, alcohol.
Esophagus	Tobacco, alcohol.
Gastric	Tobacco.
Colon	Tobacco, alcohol.
Liver	Aflatoxin, vinyl chloride, tobacco, alcohol.
Kidney	Tobacco, trichloroethylene.
Bladder	Tobacco, 4-amino biphenyl, 2-naphthylamine, cyclophosphamide, phenacetin.
Prostate	Cadmium.

Skin	Arsenic, coal tar, PAH, benzopyrenes, cyclosporin A.
------	--

Chemical carcinogens

Genotoxic	Non-genotoxic
Directly altering genetic material.	Independent of direct insult.
Damages DNA by : <ul style="list-style-type: none"> • DNA adducts. • Inducing DNA ssb (single stranded breaks) & dsb (double stranded breaks). 	MAP (mitogen activated protein) kinase pathway (or) NFkB pathway They are epigenetic modifiers : <ul style="list-style-type: none"> • Cytotoxic. • Receptor mediated (steroid receptors & tamoxifen)
<ul style="list-style-type: none"> • Direct genotoxic : Cause cancer at site of exposure. E.g : UV induced skin cancer. • Indirect genotoxic : Require metabolic transformation from procarcinogen to carcinogen E.g : Aflatoxin. 	

Both can cause reactive oxygen species DNA damage alter gene expression.

Aristolochic acid :

- From genus of Aristolochia (plant).
- used as herbal remedy for weight loss.
- Class I carcinogen.
- Causes A : T to T : A transversion.

- Diseases caused :
 - c. Balkan endemic nephropathy.
 - d. Nephrotoxic → Interstitial fibrosis.
 - e. upper tract urothelial carcinoma.

PAH (Polycyclic aromatic hydrocarbons) :

- ≥ 3 fused benzene rings.
- >200 chemicals.
- Benzopyrene : most studied PAH.
- metabolized by CYP4501A1 & CYP4503A4.
- mechanism of action : DNA adducts formation.
- Excretion : Glutathione pathway.
- ↑ risk lung & skin cancer.
- Found in overcooked food, coal burning and tobacco smoke.

IARC group I pharmaceutical carcinogens

00:35:13

Drug	Cancer
Azathioprine	Non-hodgkin's lymphoma, SCC of skin, HCC, cholangiocarcinoma.
Cyclophosphamide	Bladder cancer, leukemia.
Chlorambucil	Leukemia
Cyclosporine	Leukemia, lymphoma, non-melanomatous skin cancer.
Tamoxifen	Endometrial cancer
Estrogen /OCP /HRT.	Breast cancer, endometrial cancer.

Physical factors :

- Ionising radiations : Ionize molecules (electron is displaced from orbit) by linear energy transfer (LET)
- Electromagnetic radiation : X rays & γ rays (have low LET).
- Particulate matter : Electron, proton, neutron, Carbon ion, α particles (have high LET).

m/c source of radiation exposure :

- 80% : Radon gas.
- 20% : medical sources.

Mechanism of action of ionising radiations

00:39:29

Direct action	Indirect action
High LET : Direct DNA damage	Low LET
Direct energy transfer to molecule.	Hydrolysis of H_2O releases \rightarrow OH^\cdot radical \rightarrow DNA damage.

Both causes similar lesions in DNA.

1 Gy of ionizing radiation :

- 40 dsb formed \rightarrow Critical lesions \rightarrow Cell lethality.
- 1000 ssb formed
- 1000 single base lesions destroyed.
- 150 DNA protein crosslinks formed per cell.

Cell response to radiation :

1. Base excision repair : For ssb.
2. Homologous repair :
 - a. High fidelity repair (requires a contralateral DNA strand).
 - b. For dsb.
3. Non homologous end joining repair :
 - a. m/c mechanism of repair in ionising radiations.
 - b. For dsb.
 - c. Not accurate : Results in mutation.

Theoretical risk models for radiation induced cancer

00:43:46

1. Linear, no threshold model :

- most accepted
- Induction of cancer is directly proportional to dose of radiation (even in low dose).

2. Sublinear / threshold model : Below threshold dose, risk is negligible.

3. Supralinear / Stealth model :

- Doses below threshold can trigger activation of DNA damage surveillance & repair mechanism → Sub-optimal activation of cell cycle.
- ↑ sed chance of mutation accumulation → Cancer.

4. Linear quadratic model : Radiation at low doses → Single tract of radiation hitting multiple targets → Quadratic induction rate.

Tissue vulnerable to radiation :

vulnerability	Tissue / cells
most vulnerable	Hematopoietic cell line (↑ all leukemia except CLL) > Thyroid gland
Intermediate	Breast, lung, salivary gland
Radioresistant	Skin, bone, GIT.

ETIOLOGY OF CANCER II


Physical factors leading to carcinogenesis

00:00:08

uv light :

- UV A (320 to 400 nm) : mainly produces ROS → Single strand breaks & base lesions in DNA.
- UV B (290 to 320 nm).
- UV C (240 to 290 nm) : most damaging to DNA. most of the UV C is absorbed by ozone layer.
- UV B & UV C : Forms pyrimidine dimers. And also 6 - 4 photoproducts that consists of covalent ring structures → Bending of DNA helix → Interfere in DNA synthesis.

Cellular reponse to UV radiation :



Asbestos :

- Contributes in causing 5 - 7 % of all lung cancers.
- mechanism of action : ROS → Single strand breaks + base lesions.
- Asbestos + tobacco : more chance of causing lung CA.
- Tumor suppressor genes p53 & p16INK4A + K-RAS oncogene are associated with lung CA caused by asbestos.